Recent Research into the Alpha-SynucleinalphaSyn or SNCA-Pipeline Review, H1 2016

Alpha-SynucleinalphaSyn or SNCA-Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on Alpha-Synuclein (alphaSyn or SNCA) targeted pipeline therapeutics.

The report provides comprehensive information on the Alpha-Synuclein (alphaSyn or SNCA), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics development and features dormant and discontinued projects.

To view the table of contents and know more details please visit Alpha-SynucleinalphaSyn or SNCA-Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report reviews key players involved in Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics

Reasons to buy

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Alpha-Synuclein (alphaSyn or SNCA)
- Devise corrective measures for pipeline projects by understanding Alpha-Synuclein (alphaSyn or SNCA) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

AC Immune SA AFFiRiS AG BioArctic Neuroscience AB Biogen, Inc. NeuroPhage Pharmaceuticals, Inc. Neuropore Therapies, Inc. nLife Therapeutics, S.L. Primary Peptides, Inc. Prothena Corporation Plc QR Pharma, Inc. reMYND NV Synovo GmbH

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###